MADRID, Spain – June, 2026
Corify Care expands its clinical footprint to the United States with the initiation of the ACORYS-AI4AF trial at Mayo Clinic. The study will evaluate the clinical impact of instant, Global Cardiac Mapping in the treatment of Atrial Fibrillation.
At Corify Care, our mission is to provide electrophysiologists with the tools they need to treat complex arrhythmias with absolute confidence.
Evaluating Global Cardiac Mapping in AF
The AI4AF clinical trial is designed to evaluate how our 4D FAST-MAP technology supports clinical decision-making in patients with AF. Specifically, it will assess whether ACORYS can identify patients likely to benefit from PVI alone versus those requiring additional ablation targets beyond PVI.
Selecting the right AF ablation strategy remains challenging, particularly when defining patient-specific ablation targets beyond PVI in these complex and chaotic rhythms.Corify Care addresses this gap by delivering instant, whole-heart insight in a single beat. Our system is designed to seamlessly complement standard catheter ablation workflows, giving physicians a complete panoramic view of the heart’s electrical activity before making the first burn.
Clinical Clarity for the EP Lab
By integrating our technology into the clinical workflow at one of the world’s leading medical institutions, the AI4AF trial aims to demonstrate three core benefits for the EP lab:
• Faster decisions: Reducing exploratory mapping time.
• Greater precision: Identifying stable arrhythmia drivers instantly.
• Less uncertainty: Empowering clinicians to plan their ablation strategy with a clear roadmap.
“This trial is a key milestone in our U.S. expansion and brings us one step closer to making instant Clinical Clarity the standard of care in every EP lab.” said Andreu Climent, PhD, CEO of Corify Care.
We extend our deepest gratitude to all the team at Mayo Clinic for their leadership and collaboration on this project.
View the AI4AF Clinical Trial Details Here
Learn more about our Global Cardiac Mapping Technology
The ACORYS Mapping System complies with European regulations (CE marking) and U.S. regulatory requirements, having successfully obtained FDA 510(k) clearance.
About Corify Care: Corify Care is a MedTech company redefining cardiac mapping with global, whole-heart visualization. Its technology integrates seamlessly into existing EP workflows, acting as the ultimate complement to catheter ablation and helping clinicians treat complex arrhythmias with greater confidence and efficiency.
Media Contact: Corify Care SL
